Bat SARS-like coronavirus (SL-CoV) has a genome organization almost identical to that of SARS-CoV, but the N-terminus of the Spike (S) proteins, which interacts with host receptor and is a major target of neutralizing antibodies against CoVs, of the two viruses has only 63-64% sequence identity. Although there have been reports studying the overall immunogenicity of S SL , knowledge on the precise location of immunodominant determinants for S SL is still lacking. In this study, using a series of truncated expressed S SL fragments and S SL specific mouse sera, we identified two immunogenic determinants for S SL . Importantly, one of the two regions seems to be located in a region not shared by known immunogenic determinants of the S SARS . This finding will be of potential use in future monitoring of SL-CoV infection in bats and spillover animals and in development of more effective vaccine to cover broad protection against this new group of coronaviruses.
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Bat; SL-CoV; Immune; Vaccine Since the first description of SARS-like coronavirus (SL-CoV) (Lau S K, et al., 2005; Li W, et al., 2005) , there have been successive reports on the detection of this group of new coronaviruses in bats around the world (Lau S K, et al., 2010; Ren W, et al., 2006; Tang X C, et al., 2006; Yuan J, et al., 2010) . A pathogenicity study using synthesized SL-CoV showed that it could cause disease in mice if it acquired a small fragment from SARS-CoV (Becker M M, et al., 2008) . These works highlighted the potential for SL-CoV to spillover into non-bat mammals, including humans, and cause disease.
The SARS-CoV spike protein (S SARS ) is responsible for receptor binding and is also a major target of neutralizing antibodies (He Y, 2006) . Based on the significant sequence difference between the SL-CoV spike protein (S SL ) and S SARS , it is no surprising to find that sera from SL-CoV positive failed to neutralize SARS-CoV . In our previous study, we found that SL-CoV infected bat sera could recognize a HIV-pseudovirus carrying the S SL protein, but not a similar pseudovirus carrying a mutant S SL protein with its receptor binding region replaced by that from the S SARS protein (Zhou P, et al., 2009) . From that study, we postulated that the major immunodominant neutralizing epitope may lie in this region of the S SL protein.
Using five truncated expressed proteins and a panel of S SL -specific mouse polyclonal and monoclonal antibodies, we identified two immunogenic determinants, one of which is located in a different region from those identified for S SARS . This is the first report to identify immunogenic determinants on S SL . The data presented here will be useful for future development of both diagnostics and vaccines against SL-CoV. A B Fig. 1 . Schematic diagram of S constructs and purified proteins generated in this report. A: The full-length SL-CoV S1 and the five truncated versions; the numbers shown below indicate the region (aa residue position) of each fragment. B: SDS-PAGE profile of the 6 purified proteins used in this study. The full-length S1 was expressed with MBP tag (42 kD) and the five truncated S1 were expressed in pET32a (with a 20 kD tag).
MATERIALS AND METHODS

Expression and purification of recombinant proteins
Six gene fragments covering the N-terminal S1 region of the S SL gene, as shown in Fig. 1A , were obtained by PCR using a plasmid containing the full-length S gene . Restriction enzyme sites were incorporated into each PCR primer pair, EcoR I in the forward primer and Sal I in the reverse primer, to facilitate cloning (primer sequences are available upon request). The resultant PCR fragments were purified, restriction digested and ligated into prokaryotic expression vector pET32a (Novagen) for the truncated proteins, and to pMAL-c2x vector (New England Biolabs, Inc.) for full-length S1. Plasmids were sequenced to make sure that the gene fragments are free of mutations and cloned in frame with vector encoded protein tag sequences.
The recombinant plasmids were transformed into Escherichia coli strain BL-21(DE3) (Novagen) and cultured at 37 º C until OD 600 reached 0.6 to 0.8. Protein expression was induced for 6 h with 0.3 mmol/L IPTG (isopropyl-β-Dithiogalactopyranoside) at 30 º C. Cells were harvested and resuspended in phosphate-buffered saline (PBS) and lysed by sonication after 3 cycles of freezethawing. The resulting lysates were centrifuged at 13,000×rpm for 15 min at 4 º C, and the clarified supernatants were collected and applied either to His-Bind column (Novagen) for the truncated S1 fragments or to Amylose Resin (New England Biolabs, Inc.) for full-length S1 protein according to the manufacturers' protocols. The purity of the recombinant proteins was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Production of antibodies
Mouse sera were prepared by DNA immunization using plasmids expressing the SL-CoV Rp3 S gene as described previously (Zhou P, et al., 2009) . Monoclonal antibodies against SL-CoV S1 were made using published standard procedures (Evan G I, et al., 1985) . Briefly, BALB/c mice were immunized with purified HIV/ Rp3-S pseudotyped virus produced in our previous work (Zhou P, et al., 2009 ). Spleen cells from immunized mice were harvested and fused with Sp2/0 myeloma cells. Cell culture supernatants from the hybridoma containing wells were screened by ELISA using HIV/ Rp3-S pseudovirus and purified Rp3 S1 protein as coating antigens. Positive clones were expanded and inoculated intraperitoneally into syngeneic mice using protocol approved by the Animal Ethics Committee at the Wuhan Institute of Virology. Ascites fluids were tapped and the titers of the monoclonal antibodies were determined by ELISA. To avoid cross reaction between the monoclonal antibodies and pET32a tag protein in Western blot, all monoclonal antibodies were pre-absorbed, before use, with control E. coli lysate containing pET32a encoded proteins.
Indirect ELISA
ELISA assays were performed under standard conditions. Briefly, 96-well microtiter plates were coated with purified recombinant proteins (50 to 100 ng/well) in 0.1 mol/L carbonate buffer (pH 9.3) over night at 4 º C.
The plates were washed and blocked with 5% BSA in PBS-0.1% Tween 20, and then incubated with either mouse sera or monoclonal antibodies for 1 h at 37 º C.
Bound antibodies were detected using horseradish peroxidase-conjugated goat anti-mouse IgG (LingFei Tech., Wuhan, China) with a dilution at 1:4000. Color development was conducted using 3,3,5,5, tetramethylbenzidine (TMB) and the absorbance at 450 nm was determined after the reaction was stopped with 2 mol/L H 2 SO 4. All washes were carried out five times using PBS-0.1% Tween (2 min/wash), and all antibodies were diluted using 0.5% BSA in PBS-0.1% Tween. An appropriate negative control was included in every step.
SDS-PAGE and Western blot
Proteins were separated on 12% SDS-PAGE gels followed by Coomassie blue staining using standard procedures (Wilson C M, 1983) . For Western blot analysis, separated proteins were transferred to polyvinyldifluoride (PVDF) membrane (Millipore, Bedford, MA). The membranes were then blocked with 5% skim milk in PBS-0.1% Tween for 1h at 37 º C. After three washes, the membranes were incubated overnight at 4 º C with mouse sera at 1:1000 or monoclonal antibodies at 1:250. Bounded antibodies were detected for 1h at 37 º C with alkaline phosphatase-conjugated Affinipure goat anti-mouse IgG (Proteintech Group, Inc., Wuhan, China) at 1:2000, and developed using the TMB membrane peroxidase substrate system. The developed membranes were washed and air dried.
Sequence alignment and structure modeling
The amino acid sequences of S proteins were obtained from NCBI (GeneBank accession no. YP_001382361.1 for Rp3 S and AAP41037.1 for Tor2 S). Sequence alignment was done using Clustal W ( Thompson et al., 1994) . Protein structures were modeled using CPHmodels 3.0 (Lund et al 2002) and PyMOL 1.2.8 (DeLano scientific).
RESULTS
Expression and purification of recombinant proteins
Six recombinant proteins, including full-length S1 and five truncated fragments, were successfully expressed in E. coli. All of them were soluble, which greatly facilitated affinity purification based on their fused protein tags. After purification, the purity was analyzed by SDS-PAGE followed by Coomassie blue staining. A purity of 90% or more was achieved for all of the recombinant proteins (Fig. 1B) .
Identification of immunogenic determinants using truncated recombinant S SL fragments
Five purified S1 fragments were tested by ELISA against sera from four mice immunized with plasmid DNA encoding full-length Rp3-S. Fig. 2A summarizes the resulting immune responses in the four immunized mice. Most of the sera reacted against S 280-455 (4/4) and S 561-666 (3/4), while one animal reacted against S (1/4), and none reacted against S 1-82 (0/4) or S 82-280 (0/4) .
Mapping of immunogenic regions recognized by Rp3 S monoclonal antibodies (mAb)
HIV/Rp3-S pseudotyped virus (Ren W, et al., 2008 ) was used to immunize mouse for production of monoclonal antibodies against S SL . Successful production of antibodies was confirmed by ELISA against both HIV/Rp3-S and recombinant full-length S1 proteins, demonstrating that the mAbs reacted with the Rp3 S protein but not to the HIV pseudovirus backbone proteins (data not shown). As shown by Western blot analysis, all four mAbs reacted with the S 280-455 protein (Fig. 2B) , but not the pET32a tag protein or the other four truncated fragments (data not shown), providing further evidence that aa 280-455 is an immunogenic determinants. However, due to lacking the susceptible cell lines for SARS-like CoV Rp3, we were unable to test neutralization ability of these four mAbs.
DISCUSSION
Although there have been many studies to characterize the immunodominant determinants in SARS-CoV spike protein, S SARS (He Y, 2006; Hua R, et al., 2004) , which serves as an important target for vaccine design, there has been no report to date characterizing the immunogenic determinants for the bat SL-CoV spike protein, S SL . SL-CoV, which was first identified in 2005 (Lau S K, et al., 2005; Li W, et al., 2005) , may have the potential to spillover to humans through a minimal change in its spike protein (Lau S K, et al., 2010) . This prediction was confirmed in a recent study where a recombinant SL-CoV containing a very small fragment of the SARS-CoV S gene was able to infect and cause disease in mice, further highlighting its potential for pathogenicity in humans (Becker A B Fig. 3 . Comparison of the aa 280-504 region of S SL with the corresponding region of S SARS in SARS-CoV Tor2 S (aa 276-518). A: Alignment of the aa sequences of the two regions. The underlined region indicates the receptor binding motif (RBM) in Tor2 S. The aa residue numbers for Rp3 S and Tor2 S are provided above or beneath the sequence alignment, respectively. The key residues at aa 489 and 491 in S SARS are highlighted by asterisks. B: Structural modeling of the receptor binding motif (RBM) of Tor2 S (white) and the corresponding region in Rp3 S (black). The region present in Tor2 S but absent in Rp3 S was highlighted in yellow. M M, et al., 2008) . In view of this, defining the immunogenic determinants of S SL is necessary for both the detection of SL-CoV in bats and future vaccine design.
In the absence of a live SL-CoV, we have embarked a study to determine immunodominant determinants of S SL using mouse sera and monoclonal antibodies raised against a pseudovirus expressing the full length S SL protein. From a series of recombinant truncated S SL expressed in this study, we were able to show, by both ELISA and Western blot, that S 280-455 and S 561-666 represent two immunogenic determinants in mice. The region covering aa 280-455 was the more immunogenic of the two since it was recognized not only by the polyclonal mouse sera, but also by all four monoclonal antibodies. It is worth to mention that the S1-81 and S82-280 may also contain conformational immunogenic determinants yet not be identified by the bacteria proteins in this study. It is possible that the use of recombinant full-length S1 protein as selection antigen will result into the loss of valuable monoclonals. Further screening of more immunogenic determinants needs to be performed with protein expressed in eukaryotic cells.
From a previous report we know that aa 528-635 of S SARS is a major immunodominant determinants , and S SL shares very high sequence identity in this region . In view of this, it is not surprising that S 561-666 of S SL also demonstrated the immunogenic in mouse. However, the receptor binding domain (RBD) of S SL has low sequence identity to that of S SARS , especially in the critical receptor binding motif (RBM) region (Fig. 3A) . The RBD region of S SARS was known to be a major target of neutralizing antibodies (He Y, 2006; . The corresponding region of S SL also showed high level of immunogenicity, as reported previously (Zhou P, et al., 2009 ). However, a subtle difference was observed from this study. Although residues in the RBM region were reported to be a hotspot for neutralizing antibody production in S SARS (Zhu Z, et al., 2007) , the corresponding region (underlined in Fig.  3A ) in S SL failed to react with any of the four monoclonal antibodies and only reacted with one of the four mouse sera. From a 3D modeling of the RBM region (Fig. 3B) for the two S proteins, it is evident that the two structures are almost identical except for a few very minor differences. Interestingly, several predicted hotspots for antibody targeting in different SARS-CoV strains, especially those covering the residues 489 and 491 (Zhu Z, et al., 2007) , are highly conserved in S SL both in sequence and predicted structure. But these regions seemed to be non-immunogenic in mice from this study. This could imply a subtle, but important difference in the location of immunodominant determinants between the two S proteins. However, it has to be said that the current study 96 was based on an immunization study in mice, rather than an infection study. Further investigation is required before we can fully assess the potential immunogenicity differences of the different bat SL-CoV S proteins.
Nevertheless, it is worth noting that the antibodies generated in this study will be a useful tool in many aspects. For example, combining the S 280-455 specific mAbs and the more cross reactive N protein-specific antibodies, we can design tests that could simultaneously detect SARS-related coronaviruses as well as determine potential recombinant events in the S genes. This will be especially beneficial for the long term monitoring of SL-CoVs in bats, which is being actively pursued by many groups around the world (Lau S K, et al., 2010) .
In summary, this work represents a first attempt to determine the immunogenic determinants for S SL in comparison to S SARS . The knowledge and reagents generated from the current study will facilitate ongoing SL-CoV surveillance and research, including the development of better diagnostics and broad spectrum vaccines against this new group of coronaviruses.
